{"id":10878,"date":"2026-02-03T14:30:00","date_gmt":"2026-02-03T14:30:00","guid":{"rendered":"https:\/\/palynziqpatient-prod-001.azurewebsites.net\/en-us\/?page_id=10878"},"modified":"2026-04-07T11:06:48","modified_gmt":"2026-04-07T11:06:48","slug":"adults","status":"publish","type":"page","link":"https:\/\/palynziq.biomarin.com\/en-us\/study-results\/adults\/","title":{"rendered":"Results with adults"},"content":{"rendered":"
Before starting PALYNZIQ, people participating in the study had an average Phe level of 20 mg\/dL.<\/p>\n <\/div>\n\n
\t\t\t<\/div>\n\t\t\tTHE POWER OF CONSISTENCY<\/strong><\/span><\/p>\n Over time, people who stuck with PALYNZIQ were able to reach their treatment goals.<\/p>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n<\/div>\n\n *21% (25\/118) of patients stopped taking PALYNZIQ before reaching a Phe level below or equal to 6 mg\/dL. Of those, 10 patients stopped due to side effects. 3% (4\/118) did not reach a Phe level equal to or below 6 mg\/dL before completing the study.<\/small><\/p>\n <\/div>\n <\/div>\n <\/div>\n<\/div>\n\n